Advertisement

Topics

Study of TQB2450 Combined With Anlotinib in the Treatment of Mutation Positive Lung Cancer

2019-06-18 02:44:27 | BioPortfolio

Published on BioPortfolio: 2019-06-18T02:44:27-0400

Clinical Trials [3347 Associated Clinical Trials listed on BioPortfolio]

Study of TQB2450 Combined With Anlotinib in the Treatment of Mutation Positive Lung Cancer

This is an open-label, single center, non-randomized, phase Ib trial to evaluate safety and efficacy of TQB2450 injection combined with anlotinib in patients with advanced mutation positiv...

Study of TQB2450 Combined With Anlotinib in Patients With Advanced Non-small Cell Lung Cancer(NSCLC)

TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell acti...

Study of TQB2450 Combined With Anlotinib in Patients With Advanced Solid Tumors

TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1),which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activ...

An Phase Ib Study of TQB2450 Injection and Anlotinib Hydrochloride Capsules to Treat Triple Negative Breast Cancer (TNBC)

The purpose of this study is to evaluate the efficacy and safety of PD-L1 inhibitorin in combination with Anlotinib treatment for patients with triple receptor negative breast cancer treat...

Phase Ib Clinical Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma

A single-arm, open-label clinical trial, focus on the safety and efficacy of TQB2450 injection combined with Anlotinib hydrochloride capsule in patients with advanced biliary adenocarcinom...

PubMed Articles [16039 Associated PubMed Articles listed on BioPortfolio]

Comparison of value of biomarkers in diagnosing lung cancer: An overview of systematic reviews protocol.

In both sexes combined, lung cancer is the most commonly diagnosed cancer and the leading cause of cancer death. Furthermore, the incidence rate is increasing in many countries. Many lung cancer patie...

Lung cancer survival among never smokers.

Lung cancer incidence among never smokers has increased in recent decades with 10-30% of all lung cancers occurring in never smokers, where exposure to residential radon is the leading cause of this d...

Research progress on interleukin-6 in lung cancer.

As the core of cellular immunotherapy, T cells are important aspects of research and treatment of lung cancer. IL-6 is a costimulatory signal factor of T cells that is directly targeted by lung cancer...

Evaluation of the quality of life after surgical removal of lung cancer.

Morbidity and mortality attributed to lung cancer remain at high levels, especially where men are concerned. The surgery for lung cancer involves removing neoplastic lesions in order to save the large...

AHRR (cg05575921) methylation extent of leukocyte DNA and lung cancer survival.

Prior studies have shown that AHRR (cg05575921) hypomethylation may be a marker of smoking, lung cancer risk and potentially lung cancer survival (in some lung cancer subtypes). It is unknown if AHRR ...

Medical and Biotech [MESH] Definitions

Tumors or cancer of the LUNG.

Malignant neoplasm arising from the epithelium of the BRONCHI. It represents a large group of epithelial lung malignancies which can be divided into two clinical groups: SMALL CELL LUNG CANCER and NON-SMALL-CELL LUNG CARCINOMA.

Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER.

A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.

A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA).

More From BioPortfolio on "Study of TQB2450 Combined With Anlotinib in the Treatment of Mutation Positive Lung Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial